Published in Lab Business Week, January 1st, 2006
According to a study from Turkey, "Electrical and pharmacologic stimulation of the efferent cholinergic antiinflammatory pathway suppress the systemic inflammatory response and can prevent lethal endotoxemia. Neostigmine, a cholinergic agent, has not been tested to determine if it can prevent histopathologic organ injury in endotoxemia."
S.B. Akinci and colleagues of Hacettepe University in Ankara proposed to study "the effects of neostigmine treatment on the histopathologic organ injury inflicted by Escherichia coli endotoxin in a mouse model of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2006-01-01)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.